Conditions that affect enrollment and strategies to increase it
In the clinical research industry, non-enrolling and low-enrolling sites are not a new problem. In every kick-off meeting, study sponsors develop a strategy to combat this issue. Every major clinical research conference devotes sessions to it, and it is written about in every trade publication. Overall, the industry has spent billions of dollars trying to fix it. Nevertheless, we are still seeing 20% non-enrollment rates on average across the industry, which leads us to believe that no one has made substantial progress towards solving it.
During this webinar, we will examine three topics of consideration. First, we will focus on the recent clinical research landscape: what do the 2013-2016 enrollment trends tell us? Does Big Pharma have an easier time enrolling patients than newer, smaller biotech companies? Do technology solutions decrease the number of non-enrolling sites? Are there sponsors that will not allow a site to open without having a patient who is ready to be asked to participate in a clinical trial? Should sponsors use investigators who are new to research and, if so, how can they find them?
Second, we will determine if there are any solutions that consistently lead to better results. Are there any success stories? Or, considering that less than 5% of patients eligible for clinical research trials are actually enrolled, do we, as an industry, need to go back to the drawing board?
Finally, we will evaluate the 2017 enrollment trends. As the industry moves from larger therapeutic areas to specialized, rare disease indications, what effect will this have on enrollment? And how will it influence our enrollment strategies moving forward?
Join the WIRB-Copernicus Group for a one-hour webinar, during which industry expert Suzanne Caruso, Vice President of Clinical Solutions, will answer these questions, providing a clearer understanding of the conditions that affect enrollment, and offer strategies to ultimately increase it.
Presented by
Suzanne Caruso,
Vice President, Clinical Solutions, WIRB-Copernicus Group
Suzanne Caruso serves as the vice president of clinical solutions for the WIRB-Copernicus Group. In this role, Ms. Caruso oversees WCG’s robust suite of transformational solutions and manages the growth, development, and operational strategy relating to these services. She uses her unique expertise to design and develop new applications that positively impact the efficiency of clinical trials. Specifically, Ms. Caruso is focused on making WCG’s pharma and CRO clients successful with innovative solutions that accelerate time to market, improve safety, and boost data accuracy.
Most recently, she served as the associate director of clinical operations, oncology at Novartis. There, Ms. Caruso oversaw the Study Start-Up, Compassionate Use, Innovation and Informed Consent Departments. This enabled her to enhance innovations for clinical trials and medical functions in support of improving trial efficiency and protection of human subjects.
Her prior experience includes managing the Investigator Initiated Rare Disease Program franchise and individual patient INDs for the Midostaurin program at Novartis. Ms. Caruso was also responsible for leading two of the four full boards while serving as the senior institutional review board manager at Mount Sinai School of Medicine.
Ms. Caruso has been featured in industry publications such as PharmaVOICE and CenterWatch. She received her bachelor of arts degree in epidemiology and human geography from Middlebury College.
